Erica Weitz

Erica Weitz

Auto-generated profile, based on publicly available information

Erica Weitz

Department of Clinical, Neuro and Developmental Psychology,EMGO Institute for Health and Care Research,Vrije Universiteit Amsterdam,Van der Boechorststraat 1, 1081 BT Amsterdam,The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
EWErica S. Weitz
Erica S. Weitz
SHSteven D. Hollon
Steven D. Hollon
JTJos Twisk
Jos Twisk
ASAnnemieke van Straten
Annemieke van Straten
MHMarcus J. H. Huibers
Marcus J. H. Huibers
PCPim Cuijpers
Pim Cuijpers
There is no shortage of effective treatments for depression, including pharmacotherapy1 and psychotherapies, of which cognitive behavioral therapy (CBT) is one of the best documented.2,3 Previous meta-analyses4,5 have shown that psychotherapies are at least as effective as pharmacotherapy, used as monotherapy, in treating depression of mild and moderate symptom severity (defined by cutoff scores on depressive symptom inventories). However, less is known about the relative efficacy of psychotherapy vs pharmacotherapy in severely depressed populations.6,7

24 January 2018 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
EWErica Weitz
Erica Weitz
AKAnnet Kleiboer
Annet Kleiboer
ASAnnemieke van Straten
Annemieke van Straten
PCPim Cuijpers
Pim Cuijpers
Background: More than half of patients who present with depressive disorders also have elevated comorbid anxiety symptoms. Given the high comorbidity between these disorders, it is important to understand the extent that psychotherapies for depression additionally ameliorate symptoms of anxiety.Methods: Systematic searches were conducted in PubMed, PSYCinfo, EMBASE, and the Cochrane Registry of Controlled Trials. Included studies were randomized controlled trials that compared psychotherapy compared with a control condition for the treatment of adults with a primary diagnosis or elevated symptoms of depression and that examined the effects of treatment on anxiety outcomes. Acute phase depression and anxiety (continuous measure) outcomes were extracted. Effect sizes were calculated by subtracting the average post-treatment scores of the psychotherapy group from the average post-treatment scores of the comparison group divided by the pooled standard deviation.Results: Fifty-two studies of varying quality met the inclusion criteria. Pooled effect sizes showed that anxiety outcomes were significantly lower in the psychotherapy conditions than in control conditions at post-treatment [g = 0.52; 95% confidence interval (CI) 0.44–0.60; NNT (numbers-needed-to-treat) = 3.50]. Moderate heterogeneity was observed (I2 = 55%, 95% CI 40–66). Bivariate metaregression analysis revealed a significant association between depression and anxiety effect sizes at post-treatment Longer-term follow-ups of up to 14 months post-baseline showed indications for a small lasting effect of psychotherapy on anxiety outcomes (g = 0.27).Conclusions: This meta-analysis provides evidence that psychotherapy aimed at depression can also reduce anxiety symptoms in relation to control conditions.

1 October 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
EWErica Weitz
Erica Weitz
SHSteven D. Hollon
Steven D. Hollon
AKAd Kerkhof
Ad Kerkhof
PCPim Cuijpers
Pim Cuijpers

13 February 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
EWErica Weitz
Erica Weitz
AKAnnet Kleiboer
Annet Kleiboer
ASAnnemieke van Straten
Annemieke van Straten
SHSteven D Hollon
Steven D Hollon
PCPim Cuijpers
Pim Cuijpers
Introduction There are many proven treatments (psychotherapy, pharmacotherapy or their combination) for the treatment of depression. Although there is growing evidence for the effectiveness of combination treatment (psychotherapy + pharmacotherapy) over pharmacotherapy alone, psychotherapy alone or psychotherapy plus pill placebo, for depression, little is known about which specific groups of patients may respond best to combined treatment versus monotherapy. Conventional meta-analyses techniques have limitations when tasked with examining whether specific individual characteristics moderate the effect of treatment on depression. Therefore, this protocol outlines an individual patient data (IPD) meta-analysis to explore which patients, with which clinical characteristics, have better outcomes in combined treatment compared with psychotherapy (alone or with pill placebo), pharmacotherapy and pill placebo. Methods and Analysis Study searches are completed using an established database of randomised controlled trials (RCTs) on the psychological treatment of adult depression that has previously been reported. Searches were conducted in PubMed, PsycInfo, Embase and the Cochrane Central Register of Controlled Trials. RCTs comparing combination treatment (psychotherapy + pharmacotherapy) with psychotherapy (with or without pill placebo), pharmacotherapy or pill placebo for the treatment of adult depression will be included. Study authors of eligible trials will be contacted and asked to contribute IPD. Conventional meta-analysis techniques will be used to examine differences between studies that have contributed data and those that did not. Then, IPD will be harmonised and analysis using multilevel regression will be conducted to examine effect moderators of treatment outcomes. Dissemination Study results outlined above will be published in peer-reviewed journals. Study results will contribute to better understanding whether certain patients respond best to combined treatment or other depression treatments and provide new information on moderators of treatment outcome that can be used by patients, clinicians and researchers. Trial registration number CRD42016039028.